Biotech News
Related news
GANXGain Therapeutics2026-09-17 11:00 EST
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
TNXPTonix Pharmaceuticals2026-09-02 11:00 EST
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
HRMYHarmony Biosciences2026-08-27 12:05 EST
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
CGTXCognition Therapeutics2026-09-08 11:30 EST
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
NBIXNeurocrine Biosciences2026-09-02 20:01 EST
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
NBIXNeurocrine Biosciences2026-09-30 12:30 EST
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
XENEXenon2026-09-21 20:01 EST
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
HRMYHarmony Biosciences2026-10-01 12:05 EST
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
GANXGain Therapeutics2026-09-29 21:50 EST
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
KTTAPasithea Therapeutics2026-09-03 20:05 EST
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Xenon
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....
Recent company news
XENEXenon2026-10-02 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XENEXenon2026-09-21 20:01 EST
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
XENEXenon2026-09-17 20:01 EST
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
XENEXenon2026-09-03 20:01 EST
Xenon to Present at Wells Fargo Healthcare Conference
XENEXenon2026-08-28 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 36.57 USD
- Market cap
- 5.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States